A GLP-1 and glucagon receptor dual agonist studied in obesity and type 2 diabetes, with development and regulatory status varying by region. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICMazdutide
Weight ManagementGlucose / InsulinFat Loss
Status
Clinical Development
Related
3
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
PUBLISHED STUDY
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Subcutaneous
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
PUBLISHED STUDYDiabetes Care, 2023Verified 2026-09-13
Mazdutide is an oxyntomodulin-derived dual GLP-1 and glucagon receptor agonist. Femetric date-stamps regional development and approval context rather than assuming one global status.
Mechanism summaries are stored with field-level source provenance for editorial audit.
07
Related research goals
08
Related peptides
01PEPTIDE
Survodutide
An investigational GLP-1 and glucagon receptor dual agonist in clinical development for obesity and metabolic liver disease.
Weight ManagementAppetiteFat Loss
02PEPTIDE
Pemvidutide
An investigational GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Weight ManagementFat LossBody Composition
03PEPTIDE
Retatrutide
An investigational GIP, GLP-1 and glucagon receptor agonist studied for obesity and metabolic outcomes.